CRIS Current Research Information System

MARCHESINI REGGIANI, GIULIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 21.659
AS - Asia 17.455
EU - Europa 14.721
SA - Sud America 1.115
AF - Africa 932
OC - Oceania 25
Continente sconosciuto - Info sul continente non disponibili 5
Totale 55.912
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 21.439
VN - Vietnam 4.916
SG - Singapore 4.707
CN - Cina 4.050
GB - Regno Unito 3.847
IT - Italia 2.790
DE - Germania 1.931
HK - Hong Kong 1.206
SE - Svezia 1.165
FR - Francia 1.134
UA - Ucraina 1.000
IN - India 935
RU - Federazione Russa 829
BR - Brasile 825
IE - Irlanda 542
JP - Giappone 340
ZA - Sudafrica 338
NL - Olanda 305
EE - Estonia 274
KR - Corea 264
FI - Finlandia 251
BG - Bulgaria 151
CI - Costa d'Avorio 145
TG - Togo 130
SC - Seychelles 124
AR - Argentina 116
PH - Filippine 113
CA - Canada 108
ID - Indonesia 103
BD - Bangladesh 95
IQ - Iraq 89
JO - Giordania 87
TR - Turchia 84
NG - Nigeria 83
TH - Thailandia 82
BE - Belgio 75
CH - Svizzera 69
MX - Messico 67
PK - Pakistan 65
AT - Austria 60
ES - Italia 60
PL - Polonia 55
EC - Ecuador 53
UZ - Uzbekistan 41
GR - Grecia 37
IR - Iran 37
TW - Taiwan 35
CL - Cile 33
MY - Malesia 32
EG - Egitto 31
RO - Romania 28
SA - Arabia Saudita 26
CZ - Repubblica Ceca 24
PY - Paraguay 24
AU - Australia 22
LB - Libano 21
CO - Colombia 19
PE - Perù 19
IL - Israele 17
MA - Marocco 16
LT - Lituania 14
KZ - Kazakistan 13
OM - Oman 13
KE - Kenya 12
SY - Repubblica araba siriana 12
AE - Emirati Arabi Uniti 11
DK - Danimarca 11
HR - Croazia 11
NP - Nepal 11
TN - Tunisia 11
DO - Repubblica Dominicana 10
MD - Moldavia 10
UY - Uruguay 10
PT - Portogallo 9
VE - Venezuela 9
AZ - Azerbaigian 8
AL - Albania 7
BO - Bolivia 7
DZ - Algeria 7
HN - Honduras 7
HU - Ungheria 7
PS - Palestinian Territory 7
YE - Yemen 7
ET - Etiopia 6
LK - Sri Lanka 6
SI - Slovenia 6
AO - Angola 5
JM - Giamaica 5
MU - Mauritius 5
PA - Panama 5
SK - Slovacchia (Repubblica Slovacca) 5
A2 - ???statistics.table.value.countryCode.A2??? 4
GE - Georgia 4
NO - Norvegia 4
SN - Senegal 4
TT - Trinidad e Tobago 4
BH - Bahrain 3
MM - Myanmar 3
RS - Serbia 3
SV - El Salvador 3
Totale 55.863
Salva come PNG Salva come JPEG
Città #
Southend 3.341
Singapore 3.190
Fairfield 2.590
Ashburn 2.101
Woodbridge 1.268
Seattle 1.164
Hong Kong 1.152
San Jose 1.116
Santa Clara 1.109
Wilmington 1.106
Ho Chi Minh City 1.084
Chandler 1.051
Houston 1.049
Hanoi 975
Cambridge 913
Princeton 795
Dong Ket 678
Ann Arbor 676
Jacksonville 663
Hefei 556
Dublin 495
Beijing 483
Boardman 478
Lauterbourg 434
Bologna 348
Westminster 334
Nanjing 318
Padova 304
Tokyo 301
Berlin 276
Los Angeles 269
Helsinki 227
Seoul 202
Buffalo 194
Milan 165
New York 165
Turin 165
Saint Petersburg 161
Rome 160
Dallas 157
San Diego 155
Jinan 150
Shenyang 148
Sofia 148
Abidjan 145
Haiphong 141
Lomé 130
Frankfurt am Main 127
Da Nang 126
Council Bluffs 125
Mülheim 120
Redondo Beach 115
Hebei 97
Nanchang 96
Changsha 90
São Paulo 88
Guangzhou 87
Amman 85
Redmond 83
Tianjin 83
Abeokuta 82
Medford 80
Shanghai 79
Des Moines 74
Falls Church 74
Brussels 71
Mahé 70
The Dalles 69
Verona 69
London 65
Zhengzhou 61
Johannesburg 59
Chicago 58
Yubileyny 57
Ha Long 56
Bengaluru 53
Biên Hòa 51
Dearborn 50
Hải Dương 50
Jiaxing 50
Hangzhou 49
Munich 48
Norwalk 47
Nuremberg 47
Redwood City 46
Thái Nguyên 46
Ningbo 45
Phoenix 43
Quận Bình Thạnh 43
Bremen 42
Falkenstein 42
Olalla 41
Baghdad 40
Jakarta 40
Montreal 40
Parma 39
Can Tho 37
Paris 37
Bangkok 35
Ninh Bình 35
Totale 36.672
Salva come PNG Salva come JPEG
Nome #
Il diabete con epatopatia 826
Glucokinase Regulatory Protein Gene Polymorphism Affects Liver Fibrosis in Non-Alcoholic Fatty Liver Disease 547
Quanto mangio veramente? 531
Sexuality and psychopathological aspects in premenopausal women with metabolic syndrome. 475
Prevalenza delle disfunzioni sessuali femminili nelle donne in menopausa con sindrome metabolica. 368
Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems 337
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial 278
Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage 270
Predicting Frailty Condition in Elderly Using Multidimensional Socioclinical Databases 266
Nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease. An overview 265
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease 264
An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers 259
Does the liver accelerate ageing: Talking muscles and liver? 258
Prevalence of Sexual Dysfunction among Postmenopausal Women with and without Metabolic Syndrome. 249
Switching among Equivalents in Chronic Cardiovascular Therapies: 'Real World' Data from Italy 245
NAFLD e cirrosi epatica 240
A standard ballroom and Latin dance program to improve fitness and adherence to physical activity in individuals with type 2 diabetes and in obesity 239
Acute heart failure in the emergency department: a follow-up study 234
Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System 233
The Role of Medications for the Management of Patients with NAFLD 231
Double-heterozygous mutations involving both HNF1A (MODY3) and HNF4A (MODY1) genes: a case report 231
A controlled, class-based multicomponent intervention to promote healthy lifestyle and to reduce the burden of childhood obesity 227
Biomechanical and functional alterations in the diabetic foot: Differences between type I and type II Diabetes 221
A randomized controlled trial of metformin vs. vitamin E or prescriptive diet in non-alcoholic fatty liver disease 219
Effects of cognitive-behavioral therapy on eating disorders: neurotransmitter secretory response to treatment 218
Nonalcoholic fatty liver and insulin resistance: a cause-effect relationship? 217
Approcci nutrizionali nella steatoepatite non alcolica 215
Correlation between DXA and laboratory parameters in normal weight, overweight, and obese patients 213
Cognitive-behavioral strategies to increase the adherence to exercise in the management of obesity 212
Non-alcoholic steatohepatitis in patients cared in metabolic units 211
Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage. 211
Psychological status and depression in patients with liver cirrhosis 210
Long-term weight loss maintenance for obesity: A multidisciplinary approach 209
Association between Albumin Alterations and Renal Function in Patients with Type 2 Diabetes Mellitus 208
A physical activity program to reinforce weight maintenance following a bheavior program in overweight/obese subjects. 208
Comparison of WHO and ATPIII proposals for the definition of the metabolic syndrome in patients with Type 2 diabetes 208
Diabetes and NAFLD: a high-risk cohort with definite therapeutic potential 208
A combined HPLC-immunoenzymatic comprehensive screening for suspected drug poisoning in the emergency department 206
Emotional intelligence, emotion regulation and affectivity in adults seeking treatment for obesity. 206
The metabolic syndrome in treatment-seeking obese persons 205
Weight cycling in treatment-seeking obese persons. Data from the QUOVADIS study 200
Are behavioral approaches feasible and effective in type 2 diabetes? A propensity score analysis 200
Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C 200
Non-alcoholic fatty liver disease/Non-alcoholic steatohepatitis (NAFLD/NASH): treatment 199
Adiponectin isoforms, insulin resistance and liver histology in nonalcoholic fatty liver disease 199
Healthcare resource utilization and costs of nonalcoholic steatohepatitis patients with advanced liver disease in Italy 199
A randomized trial of energy-restricted high-protein versus high-carbohydrate, low-fat diet in morbid obesity. 194
Weight loss for a healthy liver 193
Long-term follow-up of web-based and group-based behavioural intervention in NAFLD in a real world clinical setting 192
The construct validity of the Short Form-36 health survey and its relationship with BMI in obese outpatients 192
Psychological profile and quality of life of morbid obese patients attending a cognitive behavioural program 192
Eating habits in patients affected by metabolic syndrome and liver disease (hepatitis, cirrhosis and liver transplant) 192
Reply to: “Industrial, not fruit fructose intake is associated with the severity of liver fibrosis in genotype 1 chronic hepatitis C patients” 191
Supervised vs. self-selected physical activity for individuals with diabetes and obesity: the Lifestyle Gym program 189
Cardiovascular, Ocular and Bone Adverse Reactions Associated with Thiazolidinediones: A Disproportionality Analysis of the US FDA Adverse Event Reporting System Database. 187
Psychological distress in morbid obesity in relation to weight history 186
Cognitive-behavioral treatment of nonalcoholic fatty liver disease: a propensity score-adjusted observational study 186
Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease? 185
Impaired Lipid Profile is a Risk Factor for the Development of Sexual Dysfunction in Women 184
Weight loss expectations in obese patients seeking treatment at medical centers 183
A position statement on NAFLD/NASH based on the EASL 2009 special conference 183
Pathogenetic mechanisms and cardiovascular risk: Differences between HbA1c and oral glucose tolerance test for the diagnosis of glucose tolerance 183
Effects of cognitive-behavioral treatment for weight loss in the family members 182
The association between emotional intelligence and weight loss after a psychoeducational intervention for obese patients. 182
Behavioral aspects of nonalcoholic fatty liver disease: diet, causes, and treatment 181
A psychological support program for individuals with type 1 diabetes 181
Which treatment for nonalcoholic fatty liver disease? 180
Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting 178
Progetto "GULLIVER". Intervento nutrizionale via internet nella sindrome metabolica 177
Physical activity support or weight loss counseling for nonalcoholic fatty liver disease? 176
3D bone architecture in weight-bearing combined to pressure measurements in the diabetic foot 176
Preliminary study about the possible glycemic clinical advantage in using a fixed combination of Berberis aristata and Silybum marianum standardized extracts versus only Berberis aristata in patients with type 2 diabetes. 175
The management of severe hypoglycemia by the emergency system: The HYPOTHESIS study 175
Insulin glargine improves glycemic control and health-related quality of life in type 1 diabetes 175
Combination of GLP-1 receptor agonists and behavioural treatment in type 2 diabetes elicits synergistic effects on body weight: A retrospective cohort study 174
Eating behavior affects quality of life in type 2 diabetes mellitus 173
Antiplatelet therapy and the outcome of subjects with intracranial injury: the Italian SIMEU study 173
Lifestyle changes for the treatment of nonalcoholic fatty liver disease-a 2015-19 update 173
Metabolic Syndrome and NASH 172
Lifestyle Intervention in NAFLD: Long-Term Diabetes Incidence in Subjects Treated by Web- and Group-Based Programs 171
Real-world prevalence of metabolic associated fatty liver disease (MAFLD) and fibrotic-non-alcoholic steatohepatitis (NASH) in patients with obesity (PwO) in an outpatient specialist clinic in Italy 171
Prospective validation of a proposal for diagnosis and management of patients attending the emergency department for mild head injury 171
Update on nutritional supplementation with branched-chain amino acids 171
Venesection for nonalcoholic fatty liver disease unresponsive to lifestyle counselling - a propensity score-adjusted observational study 170
Massive weight loss without surgery in a super obese patient 170
AISF position paper on nonalcoholic fatty liver disease (NAFLD): updates and future directions. 170
DXA-assessed changes in body composition in obese women following two different weight loss programs 170
Stress Hyperglycemia and Complications Following Traumatic Injuries in Individuals With/Without Diabetes: The Case of Orthopedic Surgery 169
Trattamento dell’obesità: La lezione della storia 168
Dual-Energy X-Ray Absorptiometry and Newest Technology: A Therapeutic Index for Different Treatment Programs in the Management of Obesity? 168
A 360-degree overview of body composition in healthy people: Relationships among anthropometry, ultrasonography, and dual-energy x-ray absorptiometry 168
Dapagliflozin and cardiovascular outcomes: anything else to DECLARE? 168
Vascular risk in young women with polycystic ovary and polycystic ovary syndrome 167
Sense of coherence, self-esteem, and health locus of control in subjects with type 1 diabetes mellitus with/without satisfactory metabolic control 167
Obesity-associated liver disease 166
Steatosi epatica non alcolica e obesità 165
Risk of malnutrition (over and under-nutrition): Validation of the JaNuS screening tool 165
The effect of lifestyle changes in non-alcoholic fatty liver disease 165
Compulsive exercise to control shape or weight in eating disorders: Prevalence, associated features and treatment outcome 165
Dysfunctional eating in type 2 diabetes mellitus: A multicenter Italian study of socio-demographic and clinical associations 165
Totale 21.620
Salva come PNG Salva come JPEG
Categoria #
all - tutte 151.686
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 151.686
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.885 0 0 0 0 0 0 0 0 0 333 282 1.270
2021/20226.150 612 229 456 457 679 371 171 470 242 263 1.150 1.050
2022/20235.985 685 818 315 736 420 394 253 330 1.010 178 531 315
2023/20242.040 133 318 117 148 159 360 136 194 82 161 129 103
2024/20257.476 321 1.148 597 583 1.578 394 465 210 114 358 186 1.522
2025/202616.343 1.873 1.653 1.581 1.395 1.858 1.064 1.755 1.180 3.001 983 0 0
Totale 56.698